Nu Skin Enterprises, INC

Nu Skin Enterprises stockholders approved an amended incentive plan, increasing share authorization by 2.85 million shares and extending the plan's term to 2036.

Nu Skin Enterprises reported Q1 2026 revenue of $320.6 million, meeting guidance while navigating a challenging global environment.

Nu Skin Enterprises, Inc. has entered into a new $250 million senior secured credit facility, comprising a $175 million term loan and a $75 million revolving credit facility, to refinance existing debt and support general corporate purposes.

Nu Skin Enterprises announced the resignation of CFO James Thomas and the immediate appointment of Chelsea Lantz as interim Chief Financial Officer.

Nu Skin Enterprises reported fourth quarter and full-year 2025 financial results within guidance, with over 50% growth in adjusted earnings for 2025, and provided an initial outlook for 2026, anticipating a return to revenue growth by year-end.

Nu Skin Enterprises reported third-quarter revenue and earnings per share within its guidance range, with EPS at the high end, as it prepares for the launch of its Prysm iO intelligent wellness platform and expansion into India.

Nu Skin Enterprises reports increased Q3 2025 earnings per share driven by cost management and a business sale, despite a significant decline in overall revenue and customer metrics.

Nu Skin Enterprises reported a significant increase in net income and EPS for Q2 2025, primarily driven by the sale of its Mavely business, despite a 12% decline in overall revenue and a drop in customer and sales force metrics.

Nu Skin Enterprises' Q1 2025 results show a net income increase driven by the sale of Mavely, despite a revenue decrease.

Nu Skin Enterprises experienced a 14% revenue decrease in the third quarter of 2024, alongside restructuring and impairment charges, but saw a positive shift in earnings per share compared to the previous year.

Nu Skin Enterprises reported a substantial net loss for the second quarter of 2024, primarily due to restructuring and impairment charges, alongside a decline in revenue.

Nu Skin Enterprises experienced a revenue decline in the first quarter of 2024, impacted by macroeconomic challenges and restructuring, though partially offset by growth in its Rhyz segment.

Nu Skin Enterprises' 2024 revenue reached $1.7 billion, reflecting a 12% decrease year-over-year amid challenging market conditions and strategic shifts.

Nu Skin Enterprises, Inc. outlines its share structure, voting rights, and dividend policies in its latest 10-K filing.

Director Edwina D. Woodbury acquired 19 shares of Nu Skin Enterprises, Inc. through a dividend reinvestment plan.

Nu Skin Enterprises Director James M. Winett reported transactions involving Class A Common Stock, including acquisitions and dispositions under a Rule 10b5-1 trading plan.

Nu Skin Enterprises Director Laura Nathanson acquired 26,643 shares of Class A Common Stock on June 1, 2026.

NU SKIN ENTERPRISES, INC. reports a transaction where Director Mark A. Zorko acquired 26,643 shares of Class A Common Stock.

Nu Skin Enterprises, Inc. director Edwina D. Woodbury reported transactions involving Class A Common Stock, executed under a Rule 10b5-1 trading plan.

Nu Skin Enterprises Director Emma S. Battle acquired 26,643 shares of Class A Common Stock on June 1, 2026, increasing her beneficial ownership.

Nu Skin Enterprises, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 28, 2026, to elect directors, approve executive compensation, and ratify auditor selection.

Nu Skin Enterprises, Inc. has filed a definitive proxy statement with the SEC.

Nu Skin Enterprises is asking stockholders to approve an amended incentive plan and elect nine directors at its upcoming annual meeting on May 29, 2025.

Nu Skin Enterprises, Inc. files its definitive proxy statement with the SEC.

Nu Skin Enterprises will hold its annual meeting on June 5, 2024, to vote on director elections, executive compensation, an incentive plan, and auditor ratification.

Charles Schwab Investment Management Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.45% of Nu Skin Enterprises, Inc. Class A Common Stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Nu Skin Enterprises Inc. common stock following an internal realignment.

Charles Schwab Investment Management Inc. has disclosed a 5.37% beneficial ownership stake in Nu Skin Enterprises, Inc. Class A Common Stock.

BlackRock, Inc. has filed an Amendment No. 12 to its Schedule 13G, disclosing a 7.6% beneficial ownership stake in Nu Skin Enterprises Inc.'s Class A Stock as of March 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 7.92% beneficial ownership stake in Nu Skin Enterprises Inc. as of December 31, 2024.